Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2018

01-10-2018 | Research Article

Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital

Authors: Lisper Wangeci Njeri, William Otieno Ogallo, David Gitonga Nyamu, Sylvia Adisa Opanga, Alfred Rugendo Birichi

Published in: International Journal of Clinical Pharmacy | Issue 5/2018

Login to get access

Abstract

Background

Chronic kidney disease (CKD) patients are prone to medication-related problems (MRPs). Few studies address the clinical relevance of MRPs among CKD patients in sub-Saharan Africa.

Objective

To investigate the frequency and predictors of MRPs among adult CKD patients treated at a tertiary care facility in an urban sub-Saharan setting.

Setting

Kenyatta National Hospital in Nairobi, Kenya.

Method

A cross-sectional study involving 60 adult patients with CKD was carried out. Data were collected through structured interviews and patient chart reviews between April 2016 and June 2016. MRPs identified from the collected data were classified according to Hepler and Strand classification. The frequencies of the identified MRPs were computed and logistic regression used to investigate the associations between the MRPs and covariates in the data. Main outcome measures: frequencies and predictors of MRPs.

Results

271 MRPs were identified. The commonest MRPs were drug interactions (21.8%), indication without drug (18.1%) and medication non-adherence (15.5%). Compared to patients with CKD stage 3, patients with CKD stage 4 were 5.9 times more likely to have an improper drug selection and 4.7 times more likely to experience overdosage. Other significant predictors of MRPs were the number of medications per prescription and the number of comorbidities per patient.

Conclusion

This study found a high frequency of MRPs among patients with chronic kidney disease receiving care in urban sub-Saharan tertiary hospital settings. The predictors of MRPs among CKD patients in this setting are likely to be multifactorial and include the CKD stage, polypharmacy, and comorbidities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.CrossRef Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.CrossRef
2.
go back to reference Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57-A. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57-A.
5.
go back to reference Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010;74(Suppl 1):S13–6. Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010;74(Suppl 1):S13–6.
6.
go back to reference Arogundade FA, Barsoum RS. CKD prevention in sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis. 2008;51(3):515–23.CrossRef Arogundade FA, Barsoum RS. CKD prevention in sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis. 2008;51(3):515–23.CrossRef
7.
go back to reference Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–12.CrossRef Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–12.CrossRef
8.
go back to reference Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed
9.
go back to reference Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P. Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol. 2012;25(5):782–8.CrossRef Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P. Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol. 2012;25(5):782–8.CrossRef
10.
go back to reference Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother. 2005;39(1):22–7.CrossRef Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother. 2005;39(1):22–7.CrossRef
11.
go back to reference Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598–605.CrossRef Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598–605.CrossRef
12.
go back to reference Belaiche S, Romanet T, Bell R, Calop J, Allenet B, Zaoui P. Pharmaceutical care in chronic kidney disease: experience at Grenoble University Hospital from 2006 to 2010. J Nephrol. 2012;25(4):558–65.CrossRef Belaiche S, Romanet T, Bell R, Calop J, Allenet B, Zaoui P. Pharmaceutical care in chronic kidney disease: experience at Grenoble University Hospital from 2006 to 2010. J Nephrol. 2012;25(4):558–65.CrossRef
13.
go back to reference Marquito AB, Fernandes NMDS, Colugnati FAB, Paula RBD. Identifying potential drug interactions in chronic kidney disease patients. Jornal brasileiro de nefrologia: ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2014;36(1):26–34.CrossRef Marquito AB, Fernandes NMDS, Colugnati FAB, Paula RBD. Identifying potential drug interactions in chronic kidney disease patients. Jornal brasileiro de nefrologia: ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2014;36(1):26–34.CrossRef
14.
go back to reference Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug–drug interactions among renal failure patients of nephrology ward in a South Indian Tertiary Care Hospital; 2012, p. 63–8. Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug–drug interactions among renal failure patients of nephrology ward in a South Indian Tertiary Care Hospital; 2012, p. 63–8.
15.
go back to reference Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12:35.CrossRef Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12:35.CrossRef
16.
go back to reference Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.CrossRef Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.CrossRef
17.
go back to reference Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis. 2003;41(2):386–93.CrossRef Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis. 2003;41(2):386–93.CrossRef
18.
go back to reference Magacho EJC, Ribeiro LC, Chaoubah A, Bastos MG. Adherence to drug therapy in kidney disease. Braz J Med Biol Res. 2011;44(3):258–62.CrossRef Magacho EJC, Ribeiro LC, Chaoubah A, Bastos MG. Adherence to drug therapy in kidney disease. Braz J Med Biol Res. 2011;44(3):258–62.CrossRef
20.
go back to reference Graffar M. Modern epidemiology; 1971. p. 661–9. Graffar M. Modern epidemiology; 1971. p. 661–9.
21.
go back to reference Daniel W. Biostatistics: a foundation for analysis in the health sciences (10th edition) 1999. 200–3 p. 978-1-118-30279-8. Daniel W. Biostatistics: a foundation for analysis in the health sciences (10th edition) 1999. 200–3 p. 978-1-118-30279-8.
22.
go back to reference Nyakiba JO, Kosgei RJ, Okalebo F. The extent of medication-related problems among patients at Kenyatta National Hospital Medical Wards: A 2012 Study: University of Nairobi; 2014. Nyakiba JO, Kosgei RJ, Okalebo F. The extent of medication-related problems among patients at Kenyatta National Hospital Medical Wards: A 2012 Study: University of Nairobi; 2014.
23.
go back to reference Sumaili EK, Cohen EP, Zinga CV, Krzesinski J-M, Pakasa NM, Nseka NM. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. BMC Nephrol. 2009;10:18.CrossRef Sumaili EK, Cohen EP, Zinga CV, Krzesinski J-M, Pakasa NM, Nseka NM. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. BMC Nephrol. 2009;10:18.CrossRef
24.
go back to reference National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, clasification and stratification 2002. S1-S266 p. 1-931472-10-6. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, clasification and stratification 2002. S1-S266 p. 1-931472-10-6.
26.
go back to reference Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
27.
go back to reference AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan. Int J Clin Pharm. 2013;35(5):780–9.CrossRef AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan. Int J Clin Pharm. 2013;35(5):780–9.CrossRef
28.
go back to reference Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16(193–03):11p. Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16(193–03):11p.
29.
go back to reference Khdour MR, Jarab AS, Adas HO, Samaro EZ, Mukattash TL, Hallak HO. Identification of drug-related problems: a prospective study in two general hospitals. Curr Clin Pharmacol. 2012;7(4):276–81.CrossRef Khdour MR, Jarab AS, Adas HO, Samaro EZ, Mukattash TL, Hallak HO. Identification of drug-related problems: a prospective study in two general hospitals. Curr Clin Pharmacol. 2012;7(4):276–81.CrossRef
30.
go back to reference Fox CH, Swanson A, Kahn LS, Glaser K, Murray BM. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J Am Board Family Med JABFM. 2008;21(6):522–30.CrossRef Fox CH, Swanson A, Kahn LS, Glaser K, Murray BM. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J Am Board Family Med JABFM. 2008;21(6):522–30.CrossRef
31.
go back to reference Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;26(4):386–92.CrossRef Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;26(4):386–92.CrossRef
32.
go back to reference Onyango MA, Okalebo FA, Osanjo GO, Nyamu DG. Patterns of antibiotic use and dose adjustment in patients with chronic kidney disease at Kenyatta National Hospital, Kenya. Pharmacoepidemiol Drug Saf. 2013;22:485. Onyango MA, Okalebo FA, Osanjo GO, Nyamu DG. Patterns of antibiotic use and dose adjustment in patients with chronic kidney disease at Kenyatta National Hospital, Kenya. Pharmacoepidemiol Drug Saf. 2013;22:485.
33.
go back to reference Liew Y, Ang S, Kamis HJ, Tan J, Brennan M. Medication compliance and understanding in pre-end stage renal disease. Nephrology. 2010;15:33–4. Liew Y, Ang S, Kamis HJ, Tan J, Brennan M. Medication compliance and understanding in pre-end stage renal disease. Nephrology. 2010;15:33–4.
34.
go back to reference Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87.CrossRef Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87.CrossRef
35.
go back to reference Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Pharmacotherapy. 2014;34(12):1330–5.CrossRef Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Pharmacotherapy. 2014;34(12):1330–5.CrossRef
36.
go back to reference Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc JAPhA. 2008;48(3):341–53. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc JAPhA. 2008;48(3):341–53.
37.
go back to reference Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc JAPhA. 2008;48(2):203–11 (3 p following 11).CrossRef Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc JAPhA. 2008;48(2):203–11 (3 p following 11).CrossRef
Metadata
Title
Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital
Authors
Lisper Wangeci Njeri
William Otieno Ogallo
David Gitonga Nyamu
Sylvia Adisa Opanga
Alfred Rugendo Birichi
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0651-7

Other articles of this Issue 5/2018

International Journal of Clinical Pharmacy 5/2018 Go to the issue